(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Ukraine: Russians abduct 50 Ukrainians from border village in Sumy - 2New science points to 4 distinct types of autism
- 3Germany's Pistorius: NATO protects Europe from Iranian missiles
- 4KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- 5A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Boeing's troubled capsule won't carry astronauts on next space station flight
- 5 Affordable Travel Destinations To Visit In South America
- Instructions to Warmly greet Discretion and Thoughtfulness
- Vote In favor of Your Favored Language Interpretation Administration
- 10 Energizing Vocations in the Innovation Business
- Incredible Travel Objections for Craftsmanship Darlings to Visit
- RSF attack on Sudan’s South Kordofan kills at least 14, including children
- Artemis 2 astronauts — now halfway to the moon — report 'burning smell' from toilet, but everything's fine
- Malaysian broadcaster rejects altered graphic about electricity rate hike
